Background: There are few safe effective ways to relieve osteoarthritis (OA) pain; as a result, off-label psychotropic drug prescriptions have increased worldwide. This study examined the change in psychotropic drug prescriptions for patients with OA from 2011 to 2020 using the Korean National Health Insurance Service dataset. Methods: The study population consisted of patients with hip or knee OA aged ≥ 65 years.Psychotropic drugs included opioids, benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), anti-epileptics, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), typical antipsychotics, atypical antipsychotics, and anxiolytics. The prevalence and long-term (> 3 months) prescription rates of psychotropic drugs in OA patients were calculated. Results: The study included 1,821,158 patients with OA (mean age 71.7 years; 65.32% female).Of the cohort, 49% had comorbidities for which psychotropics were indicated. The prevalence of psychotropic prescriptions decreased from 58.2% to 52.0% in 2018 and then leveled off.The long-term prescription rate remained constant until 2018 and then increased slightly.The most commonly prescribed psychotropics were opioids and long- and short-acting benzodiazepines. The prescription rates of opioids and long-acting benzodiazepines decreased from 2011 to 2020. For those with psychiatric co-morbidities, the prescription rates of anti-epileptics and SNRIs increased, while the prescription rates of anti-epileptics, SSRIs, other antidepressants, and atypical psychotropics increased for those without such co-morbidities. The most commonly prescribed psychotropics were diazepam and alprazolam, excluding tramadol and tramadol–acetaminophen combination. For those with psychiatric co-morbidities, the prescription rates of gabapentin and fentanyl increased, while for those without such co-morbidities, the prescription rates of lorazepam, fentanyl, escitalopram and quetiapine increased. Conclusion A significant number of older Korean patients with OA were prescribed psychotropic drugs in the absence of comorbidities requiring such drugs, including drugs that have little effect on OA and unfavorable safety profiles in older adults.

Background: There are few safe effective ways to relieve osteoarthritis (OA) pain; as a result, off-label psychotropic drug prescriptions have increased worldwide. This study examined the change in psychotropic drug prescriptions for patients with OA from 2011 to 2020 using the Korean National Health Insurance Service dataset. Methods: The study population consisted of patients with hip or knee OA aged ≥ 65 years.Psychotropic drugs included opioids, benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), anti-epileptics, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), typical antipsychotics, atypical antipsychotics, and anxiolytics. The prevalence and long-term (> 3 months) prescription rates of psychotropic drugs in OA patients were calculated. Results: The study included 1,821,158 patients with OA (mean age 71.7 years; 65.32% female).Of the cohort, 49% had comorbidities for which psychotropics were indicated. The prevalence of psychotropic prescriptions decreased from 58.2% to 52.0% in 2018 and then leveled off.The long-term prescription rate remained constant until 2018 and then increased slightly.The most commonly prescribed psychotropics were opioids and long- and short-acting benzodiazepines. The prescription rates of opioids and long-acting benzodiazepines decreased from 2011 to 2020. For those with psychiatric co-morbidities, the prescription rates of anti-epileptics and SNRIs increased, while the prescription rates of anti-epileptics, SSRIs, other antidepressants, and atypical psychotropics increased for those without such co-morbidities. The most commonly prescribed psychotropics were diazepam and alprazolam, excluding tramadol and tramadol–acetaminophen combination. For those with psychiatric co-morbidities, the prescription rates of gabapentin and fentanyl increased, while for those without such co-morbidities, the prescription rates of lorazepam, fentanyl, escitalopram and quetiapine increased. Conclusion A significant number of older Korean patients with OA were prescribed psychotropic drugs in the absence of comorbidities requiring such drugs, including drugs that have little effect on OA and unfavorable safety profiles in older adults.

Background: There are few safe effective ways to relieve osteoarthritis (OA) pain; as a result, off-label psychotropic drug prescriptions have increased worldwide. This study examined the change in psychotropic drug prescriptions for patients with OA from 2011 to 2020 using the Korean National Health Insurance Service dataset. Methods: The study population consisted of patients with hip or knee OA aged ≥ 65 years.Psychotropic drugs included opioids, benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), anti-epileptics, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), typical antipsychotics, atypical antipsychotics, and anxiolytics. The prevalence and long-term (> 3 months) prescription rates of psychotropic drugs in OA patients were calculated. Results: The study included 1,821,158 patients with OA (mean age 71.7 years; 65.32% female).Of the cohort, 49% had comorbidities for which psychotropics were indicated. The prevalence of psychotropic prescriptions decreased from 58.2% to 52.0% in 2018 and then leveled off.The long-term prescription rate remained constant until 2018 and then increased slightly.The most commonly prescribed psychotropics were opioids and long- and short-acting benzodiazepines. The prescription rates of opioids and long-acting benzodiazepines decreased from 2011 to 2020. For those with psychiatric co-morbidities, the prescription rates of anti-epileptics and SNRIs increased, while the prescription rates of anti-epileptics, SSRIs, other antidepressants, and atypical psychotropics increased for those without such co-morbidities. The most commonly prescribed psychotropics were diazepam and alprazolam, excluding tramadol and tramadol–acetaminophen combination. For those with psychiatric co-morbidities, the prescription rates of gabapentin and fentanyl increased, while for those without such co-morbidities, the prescription rates of lorazepam, fentanyl, escitalopram and quetiapine increased. Conclusion A significant number of older Korean patients with OA were prescribed psychotropic drugs in the absence of comorbidities requiring such drugs, including drugs that have little effect on OA and unfavorable safety profiles in older adults.

Background: There are few safe effective ways to relieve osteoarthritis (OA) pain; as a result, off-label psychotropic drug prescriptions have increased worldwide. This study examined the change in psychotropic drug prescriptions for patients with OA from 2011 to 2020 using the Korean National Health Insurance Service dataset. Methods: The study population consisted of patients with hip or knee OA aged ≥ 65 years.Psychotropic drugs included opioids, benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), anti-epileptics, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), typical antipsychotics, atypical antipsychotics, and anxiolytics. The prevalence and long-term (> 3 months) prescription rates of psychotropic drugs in OA patients were calculated. Results: The study included 1,821,158 patients with OA (mean age 71.7 years; 65.32% female).Of the cohort, 49% had comorbidities for which psychotropics were indicated. The prevalence of psychotropic prescriptions decreased from 58.2% to 52.0% in 2018 and then leveled off.The long-term prescription rate remained constant until 2018 and then increased slightly.The most commonly prescribed psychotropics were opioids and long- and short-acting benzodiazepines. The prescription rates of opioids and long-acting benzodiazepines decreased from 2011 to 2020. For those with psychiatric co-morbidities, the prescription rates of anti-epileptics and SNRIs increased, while the prescription rates of anti-epileptics, SSRIs, other antidepressants, and atypical psychotropics increased for those without such co-morbidities. The most commonly prescribed psychotropics were diazepam and alprazolam, excluding tramadol and tramadol–acetaminophen combination. For those with psychiatric co-morbidities, the prescription rates of gabapentin and fentanyl increased, while for those without such co-morbidities, the prescription rates of lorazepam, fentanyl, escitalopram and quetiapine increased. Conclusion A significant number of older Korean patients with OA were prescribed psychotropic drugs in the absence of comorbidities requiring such drugs, including drugs that have little effect on OA and unfavorable safety profiles in older adults.

Background: Stress management is an important component of management of mental health. Stress processing can be understood as the appraisal of and coping with stress. This study aimed to compare positive and negative perceptions of stress according to patterns of coping strategies. Methods: The study recruited 116 college students who completed the Perceived Stress Scale and Coping Inventory for Stressful Situations using a tablet PC or smartphone application. K-means cluster analysis was used to categorize the subjects into three clusters. Results: Positive perceptions were highest in Cluster 2 (i.e., task and avoidance dominant) at 3.18±0.66 followed by 2.30±0.65 in Cluster 1 (passive coping) and lowest in Cluster 3 (emotion dominant) at 1.75±0.63. Negative perceptions were highest in Cluster 3 at 2.45±0.66 followed by Cluster 1 at 1.66±0.65 and Cluster 2 at 1.07±0.68. Conclusion Differences in coping patterns can reduce the negative effects of stress. Thus, assessing the perception and management of stress can be useful and help people change their coping styles to more adaptive ones. Toward this end, a mobile application can be an appropriate tool.

Background: Stress management is an important component of management of mental health. Stress processing can be understood as the appraisal of and coping with stress. This study aimed to compare positive and negative perceptions of stress according to patterns of coping strategies. Methods: The study recruited 116 college students who completed the Perceived Stress Scale and Coping Inventory for Stressful Situations using a tablet PC or smartphone application. K-means cluster analysis was used to categorize the subjects into three clusters. Results: Positive perceptions were highest in Cluster 2 (i.e., task and avoidance dominant) at 3.18±0.66 followed by 2.30±0.65 in Cluster 1 (passive coping) and lowest in Cluster 3 (emotion dominant) at 1.75±0.63. Negative perceptions were highest in Cluster 3 at 2.45±0.66 followed by Cluster 1 at 1.66±0.65 and Cluster 2 at 1.07±0.68. Conclusion Differences in coping patterns can reduce the negative effects of stress. Thus, assessing the perception and management of stress can be useful and help people change their coping styles to more adaptive ones. Toward this end, a mobile application can be an appropriate tool.

Background: Stress management is an important component of management of mental health. Stress processing can be understood as the appraisal of and coping with stress. This study aimed to compare positive and negative perceptions of stress according to patterns of coping strategies. Methods: The study recruited 116 college students who completed the Perceived Stress Scale and Coping Inventory for Stressful Situations using a tablet PC or smartphone application. K-means cluster analysis was used to categorize the subjects into three clusters. Results: Positive perceptions were highest in Cluster 2 (i.e., task and avoidance dominant) at 3.18±0.66 followed by 2.30±0.65 in Cluster 1 (passive coping) and lowest in Cluster 3 (emotion dominant) at 1.75±0.63. Negative perceptions were highest in Cluster 3 at 2.45±0.66 followed by Cluster 1 at 1.66±0.65 and Cluster 2 at 1.07±0.68. Conclusion Differences in coping patterns can reduce the negative effects of stress. Thus, assessing the perception and management of stress can be useful and help people change their coping styles to more adaptive ones. Toward this end, a mobile application can be an appropriate tool.

Background: Stress management is an important component of management of mental health. Stress processing can be understood as the appraisal of and coping with stress. This study aimed to compare positive and negative perceptions of stress according to patterns of coping strategies. Methods: The study recruited 116 college students who completed the Perceived Stress Scale and Coping Inventory for Stressful Situations using a tablet PC or smartphone application. K-means cluster analysis was used to categorize the subjects into three clusters. Results: Positive perceptions were highest in Cluster 2 (i.e., task and avoidance dominant) at 3.18±0.66 followed by 2.30±0.65 in Cluster 1 (passive coping) and lowest in Cluster 3 (emotion dominant) at 1.75±0.63. Negative perceptions were highest in Cluster 3 at 2.45±0.66 followed by Cluster 1 at 1.66±0.65 and Cluster 2 at 1.07±0.68. Conclusion Differences in coping patterns can reduce the negative effects of stress. Thus, assessing the perception and management of stress can be useful and help people change their coping styles to more adaptive ones. Toward this end, a mobile application can be an appropriate tool.

Background: Stress management is an important component of management of mental health. Stress processing can be understood as the appraisal of and coping with stress. This study aimed to compare positive and negative perceptions of stress according to patterns of coping strategies. Methods: The study recruited 116 college students who completed the Perceived Stress Scale and Coping Inventory for Stressful Situations using a tablet PC or smartphone application. K-means cluster analysis was used to categorize the subjects into three clusters. Results: Positive perceptions were highest in Cluster 2 (i.e., task and avoidance dominant) at 3.18±0.66 followed by 2.30±0.65 in Cluster 1 (passive coping) and lowest in Cluster 3 (emotion dominant) at 1.75±0.63. Negative perceptions were highest in Cluster 3 at 2.45±0.66 followed by Cluster 1 at 1.66±0.65 and Cluster 2 at 1.07±0.68. Conclusion Differences in coping patterns can reduce the negative effects of stress. Thus, assessing the perception and management of stress can be useful and help people change their coping styles to more adaptive ones. Toward this end, a mobile application can be an appropriate tool.

Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in South Korea. Methods: This population-based retrospective, single-arm, observational study used the Korean National Health Insurance database to identify patients with HCC who received sorafenib between July 1, 2008, and December 31, 2014. A total of 9,923 patients were recruited in this study. Results: Among 9,923 patients, 6,669 patients (68.2%) received loco-regional therapy prior to sorafenib, and 1,565 patients (15.8%) received combination therapy with concomitant sorafenib;2,591 patients (26.1%) received rescue therapy after sorafenib, and transarterial chemoembolization was the most common modality applied in 1,498 patients (15.1%). A total of 3,591 patients underwent rescue therapy after sorafenib, and the median overall survival was 14.5 months compared to 4.6 months in 7,332 patients who received supportive care after sorafenib. The mean duration of sorafenib administration in all patients was 105.7 days; 7,023 patients (70.8%) received an initial dose of 600 to 800 mg. The longest survival was shown in patients who received the recommended dose of 800 mg, subsequently reduced to 400 mg (15.0 months). The second longest survival was demonstrated in patients with a starting dose of 800 mg, followed by a dose reduction to 400–600 mg (9.6 months). Conclusions Real-life data show that the efficacy of sorafenib seems similar to that observed in clinical trials, suggesting that appropriate subsequent therapy after sorafenib might prolong patient survival.